EUVIMEDEUVIMED entdecken
Crossref

Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development

Meir Bialer iD, Svein I Johannessen iD, Matthias J Koepp iD, Emilio Perucca iD, Piero Perucca iD, Torbjörn Tomson iD, H Steve White iD

Epilepsia · 2024-10 · 65 (10) · 2831-2857

DOI: 10.1111/epi.18056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, online erschienen am 15.07.2024. Verfasst von Meir Bialer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Drug Research, School of Pharmacy, Faculty of Medicine and David R. Bloom Center for Pharmacy, Hebrew University of Jerusalem, Jerusale…. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Seizures. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For >30 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided a forum for the discussion of advances in the development of new therapies for seizures and epilepsy. The EILAT XVII conference took place in Madrid, Spain, on May 5–8, 2024. Participants included basic scientists and clinical investigators from industry and academia, other health care professionals, and representatives from lay organizations. We summarize in this article information on treatments in preclinical and in early clinical development discussed at the conference. These include AMT‐260, a gene therapy designed to downregulate the expression of Glu2K subunits of kainate receptors, in development for the treatment of drug‐resistant seizures associated with mesial temporal sclerosis; BHV‐7000, a selective activator of heteromeric Kv7.2/7.3 potassium channels, in development for the treatment of focal epilepsy; ETX101, a recombinant adeno‐associated virus serotype 9 designed to increase Na V 1.1 channel density in inhibitory γ‐aminobutyric acidergic (GABAergic) neurons, in development for the treatment of SCN1A ‐positive Dravet syndrome; GAO‐3‐02, a compound structurally related to synaptamide, which exerts antiseizure activity at least in part through an action on cannabinoid type 2 receptors; LRP‐661, a structural analogue of cannabidiol, in development for the treatment of seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex; OV329, a selective inactivator of GABA aminotransferase, in development for the treatment of drug‐resistant seizures; PRAX‐628, a functionally selective potent sodium channel modulator with preference for the hyperexcitable state of sodium channels, in development for the treatment of focal seizures; RAP‐219, a selective negative allosteric modulator of transmembrane α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor regulatory protein γ‐8, in development for the treatment of focal seizures; and rozanolixizumab, a humanized anti‐neonatal Fc receptor monoclonal antibody, in development for the treatment of LGI1 autoimmune encephalitis. Treatments in more advanced development are summarized in Part II of this report.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsySeizuresAnimalsHumansClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicCongresses as TopicDrug DevelopmentDrug Evaluation, Preclinical

Stichwörter der Autor:innen

AMT‐260BHV‐7000ETX101GAO‐3‐02LRP‐661OV329PRAX‐628RAP‐219antiseizure medicationsdrug developmentepilepsyrozanolixizumab

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Institute for Drug Research, School of Pharmacy, Faculty of Medicine and David R. Bloom Center for Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel.
  • National Center for Epilepsy, Sandvika, Norway.
  • Member of European Reference Network EpiCARE, Oslo University Hospital, Oslo, Norway.
  • Section for Clinical Pharmacology, Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
  • Department of Clinical and Experimental Epilepsy, University College London (UCL), Queen Square Institute of Neurology, London, UK.
  • Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Meir Bialer, Svein I Johannessen, Matthias J Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H Steve White

Zitieren

APA

Bialer, M., Johannessen, S. I., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2024). Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development. Epilepsia, 65(10), 2831-2857. https://doi.org/10.1111/epi.18056

Vancouver

Bialer M, Johannessen SI, Koepp MJ, Perucca E, Perucca P, Tomson T, et al. Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development. Epilepsia. 2024;65(10):2831-2857. doi:10.1111/epi.18056

BibTeX
@article{Bialer2024,
  author = {Bialer, Meir and Johannessen, Svein I and Koepp, Matthias J and Perucca, Emilio and Perucca, Piero and Tomson, Torbjörn and White, H Steve},
  title = {Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development},
  journal = {Epilepsia},
  year = {2024},
  volume = {65},
  number = {10},
  pages = {2831--2857},
  doi = {10.1111/epi.18056}
}
Kostenlos starten →